8-K: Current report
DEFA14A: Others
DEF 14A: Definitive information statements
8-K: Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results
8-K: Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | DEFA14A: Others
Interpace Biosciences Inc | DEF 14A: Definitive information statements
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
Interpace Biosciences Inc | 8-K: Current report
Interpace Biosciences Inc | 8-K: Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
Interpace Biosciences Inc | 8-K: Current report
No Data
No Data